Rituximab-related viral infections in lymphoma patients S Aksoy, H Harputluoglu, S Kilickap, DS Dede, O Dizdar, K Altundag, ... Leukemia & lymphoma 48 (7), 1307-1312, 2007 | 287 | 2007 |
Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer O Saatci, A Kaymak, U Raza, PG Ersan, O Akbulut, CE Banister, ... Nature communications 11 (1), 2416, 2020 | 224 | 2020 |
Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis S Aksoy, Ö Dizdar, M Hayran, H Harputluoğlu Leukemia & lymphoma 50 (3), 357-365, 2009 | 132 | 2009 |
Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor–related arthralgia O Dizdar, L Özçakar, FÜ Malas, H Harputluoglu, N Bulut, S Aksoy, ... Journal of Clinical Oncology 27 (30), 4955-4960, 2009 | 94 | 2009 |
Breast cancer subtypes and outcomes of central nervous system metastases UY Arslan, B Oksuzoglu, S Aksoy, H Harputluoglu, I Turker, Y Ozisik, ... The Breast 20 (6), 562-567, 2011 | 93 | 2011 |
Increased cancer risk in patients with periodontitis O Dizdar, M Hayran, DC Guven, TB Yılmaz, S Taheri, AC Akman, E Bilgin, ... Current Medical Research and Opinion 33 (12), 2195-2200, 2017 | 92 | 2017 |
Demographic, clinical, and pathological characteristics of Turkish triple-negative breast cancer patients: single center experience S Aksoy, O Dizdar, H Harputluoglu, K Altundag Annals of oncology 18 (11), 1904-1906, 2007 | 74 | 2007 |
Evaluation of cancer risk in patients with periodontal diseases DC Güven, Ö Dizdar, AC Akman, AE BERKER, E Yekedüz, F Ceylan, ... Turkish journal of medical sciences 49 (3), 826-831, 2019 | 67 | 2019 |
Systemic treatment in breast-cancer patients with brain metastasis C Arslan, O Dizdar, K Altundag Expert opinion on pharmacotherapy 11 (7), 1089-1100, 2010 | 59 | 2010 |
Obesity: an endocrine tumor? Ö Dizdar, E Alyamaç Medical hypotheses 63 (5), 790-792, 2004 | 57 | 2004 |
Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy MF Ozcan, O Dizdar, N Dincer, S Balcı, G Guler, B Gok, G Pektas, ... Urologic Oncology: Seminars and Original Investigations 31 (8), 1709-1715, 2013 | 56 | 2013 |
Advances in PARP inhibitors for the treatment of breast cancer O Dizdar, C Arslan, K Altundag Expert opinion on pharmacotherapy 16 (18), 2751-2758, 2015 | 54 | 2015 |
Pharmacotherapy of triple-negative breast cancer C Arslan, O Dizdar, K Altundag Expert opinion on pharmacotherapy 10 (13), 2081-2093, 2009 | 53 | 2009 |
The prevalence of usage of herbal medicines among cancer patients S Tuna, O Dizdar, M Calis system 83, 32, 2011 | 43 | 2011 |
A case report: zoledronic acid-induced anterior uveitis S Kilickap, Y Ozdamar, MK Altundag, O Dizdar Medical Oncology 25, 238-240, 2008 | 39 | 2008 |
Liver dysfunction after chemotherapy in lymphoma patients infected with hepatitis C O Dizdar, U Tapan, S Aksoy, H Harputluoglu, S Kilickap, I Barista European journal of haematology 80 (5), 381-385, 2008 | 38 | 2008 |
Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality DC Guven, TK Sahin, HC Yildirim, E Cesmeci, FGG Incesu, Y Tahillioglu, ... BMJ Supportive & Palliative Care 14 (e1), e456-e461, 2024 | 37 | 2024 |
Characteristics of breast cancer patients with central nervous system metastases: a single-center experience H Harputluoglu, O Dizdar, S Aksoy, S Kilickap, DS Dede, Y Ozisik, ... Journal of the National Medical Association 100 (5), 521-533, 2008 | 37 | 2008 |
COVID-19 pandemic: changes in cancer admissions DC Guven, BY Aktas, MS Aksun, E Ucgul, TK Sahin, HC Yildirim, G Guner, ... BMJ supportive & palliative care 14 (e1), e376-e379, 2024 | 36 | 2024 |
Biochemical markers of bone turnover in diagnosis of myeloma bone disease O Dizdar, I Barista, U Kalyoncu, O Karadag, G Hascelik, A Cila, A Pinar, ... American journal of hematology 82 (3), 185-191, 2007 | 36 | 2007 |